Ten‐Day Sequential Therapy as First‐line Treatment for Helicobacter pylori Infection in Korea: A Retrospective Study

Abstract

Ten-day sequential therapy is found to effectively eradicate H. pylori infection as first-line treatment in Korea.

Meta-Analysis of First-Line Triple Therapy forHelicobacter pyloriEradication in Korea: Is It Time to Change?

“…Adverse events were reported in 41 studies (24 RCTs and 17 observational studies) with 8,018 subjects treated with standard triple therapy (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62). The incidence of adverse events in these studies was 20.4% (95% CI, 19.6%-21.3%).…”

Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan

“…8,9 The fall in treatment success has led to the introduction of new regimens, such as a 10-day sequential therapy, 27-30 a 7-day non-bismuth-containing quadruple therapy (a PPI, amoxicillin, clarithromycin, and nitroimidazole), and a 14-day bismuthcontaining quadruple treatment (a PPI, bismuth, tetracycline and nitroimidazole). 33 However, a recent study by Choi et al reported that there were no differences in eradication rates between sequential therapy and 10-day standard triple therapy (78% vs 72%) in Korea. The therapeutic efficacy seems suboptimal for clinical use.…”

The efficacy of hybrid therapy as first‐line regimen for Helicobacter pylori infection compared with sequential therapy

“…At present, the sequential therapy is one suggested alternative first‐line strategy: several pooled data studies and meta‐analyses have shown this treatment to yield better eradication efficacy than the traditional triple therapy . In Korea, a region with relatively high antibiotic resistance, the efficacy of sequential therapy has been reported in several randomized controlled trials including our previous prospective studies . These studies initially indicated the sequential therapy to be effective, but recent results have been less satisfactory.…”